Cisplatin - NanoCarrier

Drug Profile

Cisplatin - NanoCarrier

Alternative Names: Cisplatin micellular nanoparticle; Micelplatin; Nanoplatin; NC-6004

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tokyo
  • Developer NanoCarrier; Orient Europharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Bladder cancer; Non-small cell lung cancer
  • Phase I/II Head and neck cancer

Most Recent Events

  • 13 Jun 2017 Roche plans a phase II/III trial for Non-small cell lung cancer(Monotherapy, Combination therapy, Inoperable/unresectable, Metastatic disease, Late-stage disease) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand (NCT03178552)
  • 21 Dec 2016 NanoCarrier discontinues phase I trial in Head and neck cancer in Japan
  • 07 Oct 2016 Adverse events and efficacy data from a phase Ib/II trial in Non-small cell lung cancer and Head and neck cancer presented at the 41st European Society for Medical Oncology Congress 2016 (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top